A narrative review published in Current Opinion in Clinical Nutrition and Metabolic Care summarizes what is currently known about the benefits and risks of GLP-1 receptor agonist therapy for obesity in adults aged 65 and over. The authors conclude the drugs may be a valuable option for carefully selected older patients, particularly those with severe obesity and cardiometabolic comorbidities.

GLP-1 receptor agonists are a drug class originally developed for type 2 diabetes that has since become a mainstay of weight management. The review notes that obesity in older adults is associated with osteoarthritis, impaired mobility, reduced quality of life, cardiovascular disease and other age-related conditions, which is the reason the question is being asked at all.

What the evidence shows

Studies cited in the review suggest GLP-1 RAs produce clinically meaningful weight loss in older adults, with efficacy comparable to that seen in younger populations. That is a more interesting finding than it sounds: age-related differences in drug response are common enough that parity is not the default assumption.

Selected drugs in the class have also demonstrated cardiovascular benefits, including reductions in major adverse cardiovascular events. The authors argue this may matter more in older people precisely because the baseline burden of cardiovascular disease is higher.

The risks that scale with age

The review lists several concerns to weigh before starting treatment: gastrointestinal intolerance, sarcopenia-related muscle loss, ophthalmologic complications, and hypoglycemia when the drugs are combined with insulin or sulfonylureas. Muscle loss is the one that deserves the most attention here, because an older patient losing weight is not in the same position as a 40-year-old losing the same percentage.

The authors also flag polypharmacy and age-related physiological changes as factors that may increase the likelihood of clinically relevant drug interactions. Older patients are typically on more medications, and the review treats that as a reason for caution rather than an afterthought.

Limitations

This is a narrative review, not a systematic one or a meta-analysis, so it summarizes existing evidence rather than generating or pooling it. The abstract does not report effect sizes, event rates or the number of trials considered, and it does not specify how much of the underlying data came from older adults specifically.

Bottom line

The authors' conclusion is conditional rather than enthusiastic: a valuable option for carefully selected older adults. Which patients fall inside that selection, and how muscle mass is protected during treatment, are the questions the review leaves open.